Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patients with metastatic renal cell carcinoma.
Epistemonikos ID: f80fb1af2ddc5ff1f3adb9e7948440f0b6f0b7f9
First added on: May 04, 2024